Patients with MDR/XDR-TB and DM were more likely than patients without DM to exhibit clinically greater disease severity at baseline.

Patients with MDR/XDR-TB with and without DM undergoing treatment with BDQ-containing regimens achieved equally satisfactory sputum culture conversion rates.

All patients had acceptable safety and drug tolerability after 24 weeks of treatment.